



Substitute for form 1449, PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet

1

of

1

**Complete if Known**

Application Number	10/049,427
Filing Date	May 6, 2002
First Named Inventor	Thor
Art Unit	1617
Examiner Name	Mitchell
Attorney Docket Number	4220-78-PUS

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		PCT -				
		-				
		-				

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. <sup>1</sup>	
		McMahon, C., J. Sex Med., Supp2:94-5 (2005)
		Day, SJ and Altman, DG Blinding in Clinical Trials and Other Studies, <i>British Medical Journal</i> , 321:504 (2000)
		Swartz, D.A. (1994), Sertraline hydrochloride for premature ejaculation. J Urol 151 (Suppl.); 345A

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.